Genetic Study Reveals Variability in GLP-1 Drug Efficacy and Side Effects
A recent study published in Nature has identified genetic variants that influence the efficacy and side effects of GLP-1 receptor agonists, a class of drugs used for weight loss. The research involved a genome-wide association study (GWAS) with 27,885 participants, revealing that a missense variant in the GLP1R gene is associated with enhanced weight-loss efficacy. Each copy of the effect allele predicted an additional 0.76 kg of weight loss. Additionally, genetic variations in GLP1R and GIPR were linked to medication-induced nausea and vomiting, particularly in patients using tirzepatide. The study highlights the role of genetic differences in drug-target genes in modulating therapeutic responses and adverse events. 
